A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Charlotte Lemech et al.|Annals of Oncology|2016Cited by 145
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Jean‐Charles Soria et al.|British Journal of Cancer|2019Cited by 103
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, Hui Gan et al.|Journal of Clinical Oncology|2012Cited by 14
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Anas Gazzah et al.|Journal of Clinical Oncology|2015Cited by 7
613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid TumorsHui Gan, M.J. Millward, Noelia Nebot et al.|European Journal of Cancer|2012Cited by 3